Manufacturing Vaccines
GennVax Vaccine
Facility
Manufacturing Vaccines
GennVax Vaccine
Facility
The art of vaccine production is a meticulous and strategic process, marked by a rich legacy of pioneering research and development. Thanks to substantial investment from the pharmaceutical industry, an impressive array of vaccines have emerged to combat a wide spectrum of diseases.
Traditionally, the development of a new vaccine has taken 10-15 years, with costs ranging from £374 million to £1.5 billion per vaccine. The construction of a biological manufacturing site, constituting 70% of the effort and cost, involves a staggering £448 million, with a mere 6% probability of market entry from the preclinical phase.
Despite the lengthy timeline, sustained investment and the integration of cutting-edge technologies are pivotal in controlling, and possibly eradicating, vaccine-preventable diseases.
Given these insightful details, it’s evident why global vaccine producers are poised for a captivating evolution.
However, with advancements in genetic sequencing, vaccine research and development have experienced a surge in pace. This progress sets the stage for a monumental milestone in our regional health security through the launch of Gennvax, ushering in an era of long-awaited transformation with a full production cycle facility for combined up stream and downstream technologies.
This landmark promises to be etched in the annals of our national and regional health security given the amount of effort exerted to choose our technology transfer providers who are handpicked from all across the world.
Given these insightful details, it’s evident why global vaccine producers are poised for a captivating evolution.
However, with advancements in genetic sequencing, vaccine research and development have experienced a surge in pace. This progress sets the stage for a monumental milestone in our regional health security through the launch of Gennvax, ushering in an era of long-awaited transformation with a full production cycle facility for combined up stream and downstream technologies.
This landmark promises to be etched in the annals of our national and regional health security given the amount of effort exerted to choose our technology transfer providers who are handpicked from all across the world.
We are thrilled to announce the successful signing ceremony with our esteemed Chinese partners, Minhai Beijing Biologics, renowned titans in the vaccines industry. The momentous occasion took place in Beijing at Minhai head quarters on December 11th 2023 covered by top Chinese media outlets , graced by the presence of their President and HE Chinese Head of Preventive Medicine (Chinese Ministry of Health) and the esteemed Egyptian Ambassador to China HE Mr Assem Hanafy and Dr Sherif el Feel CEO Vacsera and representative of HE egyptian minister of health Dr Khaled Abdel Ghafar.
We extend our sincerest gratitude to everyone who contributed to this pivotal technology transfer agreement, which we firmly believe will serve as a transformative cornerstone, forging a path towards vaccine manufacturing in Egypt and across Africa. This historic collaboration marks a momentous achievement in the realms of global health and security.
We strive to be the leaders, pioneers, innovators, and partners in the journey of healthcare.